Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance

Abstract

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a frequent and potentially severe complication of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell treatments. Early identification and intervention are critical to improving patient outcomes. This review explores the clinical utility of neurovascular biomarker surveillance in the early detection and prevention of ICANS, highlighting recent advances in pathophysiological understanding, risk stratification, and management strategies. Emphasis is placed on integrating biomarker-based surveillance into clinical workflows to mitigate neurotoxicity risk while maintaining immunotherapeutic efficacy.

Introduction

Immunotherapies have revolutionized the treatment landscape for hematologic malignancies, with CAR T-cell and other immune effector cell therapies showing remarkable efficacy. However, these therapies are associated with unique toxicities, most notably cytokine release syndrome (CRS) and ICANS. Neurotoxicity remains a significant barrier to safe immunotherapy administration, with variable incidence, severity, and outcomes. The implementation of reliable early detection strategies, particularly using neurovascular biomarkers, holds promise for preemptive intervention and improved survival. This article provides a comprehensive review of the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic modalities, management approaches, and recent advances related to ICANS, with a focus on neurovascular biomarker surveillance for prevention.

Epidemiology / Disease Burden

ICANS occurs in up to 40% of patients receiving CAR T-cell therapy, with higher rates observed in those treated for acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The onset typically ranges from days to weeks post-infusion. While most cases are mild and self-limited, severe neurotoxicity can result in seizures, cerebral edema, or fatal outcomes. The increasing adoption of immune effector cell therapies has expanded the at-risk population, making neurotoxicity monitoring a priority in hematology and oncology practice. The burden of ICANS extends beyond acute morbidity to include prolonged hospitalization, increased healthcare costs, and potential long-term neurocognitive sequelae.

Pathophysiology

The mechanisms underlying ICANS are multifactorial and not fully elucidated. Key contributors include endothelial activation and dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation driven by elevated cytokines such as IL-6, IL-1, and interferon-gamma. Recent studies highlight the role of neurovascular injury, with markers such as von Willebrand factor (vWF), angiopoietin-2 (Ang-2), and soluble thrombomodulin correlating with ICANS severity. Microglial activation and astrocyte dysfunction further contribute to neuronal injury. The dynamic interplay of immune activation, vascular injury, and CNS immune cell trafficking underscores the need for sensitive, mechanism-based surveillance strategies.

Risk Factors

Identified risk factors for ICANS include high tumor burden, elevated pre-therapy inflammatory markers (e.g., ferritin, CRP), prior neurologic disease, and the development of severe CRS. Certain CAR constructs, particularly those targeting CD19, have higher neurotoxicity rates. Genetic predispositions affecting endothelial function and BBB integrity are under investigation. Recent evidence suggests that early elevations in neurovascular biomarkers, such as Ang-2 and vWF, may predict subsequent ICANS development, providing a valuable risk stratification tool.

Clinical Features

ICANS presents with a spectrum of neurological symptoms, most commonly encephalopathy, aphasia, tremor, and confusion. Severe cases may progress to seizures, cerebral edema, or coma. Clinical grading scales, such as the ICE (Immune Effector Cell-Associated Encephalopathy) score, facilitate standardized assessment. Early, subtle neurocognitive changes can precede overt neurotoxicity, emphasizing the importance of vigilant monitoring and prompt evaluation of any neurological complaint in high-risk patients.

Diagnosis

Diagnosis of ICANS is primarily clinical, supported by neurological examination and grading scales. Neuroimaging, such as MRI, is typically reserved for severe or atypical presentations to exclude alternative etiologies. Laboratory evaluation may reveal elevated cytokines and neurovascular biomarkers. Recent research supports the use of serial measurement of markers like vWF, Ang-2, and S100B to detect early endothelial activation and BBB disruption prior to clinical symptom onset. Incorporating these biomarkers into routine surveillance protocols may enable preemptive intervention and improved outcomes.

Treatment & Management

Management of ICANS involves prompt cessation of immune effector cell infusion (if ongoing), supportive care, and pharmacologic intervention. Corticosteroids remain the mainstay of treatment, with dexamethasone preferred for its CNS penetration. Tocilizumab is effective for CRS but has limited efficacy in isolated ICANS. Seizure prophylaxis with levetiracetam is commonly employed in high-risk patients. Early biomarker-guided intervention, including preemptive corticosteroids or anti-cytokine therapies, is an emerging strategy, aiming to mitigate neurotoxicity severity without compromising immunotherapy efficacy.

Recent Advances / Emerging Therapies

Recent advances in the field include the identification and validation of neurovascular biomarkers for early ICANS detection. Prospective studies demonstrate that rising Ang-2 and vWF levels precede clinical neurotoxicity, offering a window for intervention. Novel approaches targeting endothelial protection (e.g., defibrotide), BBB stabilization, and modulation of CNS inflammation are under investigation. Integration of real-time biomarker surveillance into electronic health records and clinical decision support systems may enable timely risk stratification and intervention. Additionally, modified CAR constructs with reduced cytokine release profiles are being developed to minimize neurotoxicity risk.

Guideline Recommendations

Current guidelines from the American Society for Transplantation and Cellular Therapy (ASTCT) and other expert panels recommend routine neurological assessment and standardized grading of ICANS in all patients receiving immune effector cell therapies. Emerging recommendations support the incorporation of neurovascular biomarker monitoring in high-risk populations, with serial measurements guiding escalation of monitoring and early initiation of preventive therapies. Multidisciplinary care, including neurology consultation and intensive care support for severe cases, is essential for optimal patient outcomes.

Conclusion

ICANS remains a significant complication of immune effector cell therapies, necessitating vigilant surveillance and timely intervention. Early neurovascular biomarker monitoring represents a promising approach to risk stratification and prevention, potentially reducing morbidity and improving overall safety. Ongoing research and integration of biomarker-driven protocols into clinical practice will be critical for maximizing the therapeutic potential of immunotherapies while safeguarding neurological function.